GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Genetic Technologies Corp (NAS:AGTC) » Definitions » Retained Earnings

Applied Genetic Technologies (Applied Genetic Technologies) Retained Earnings : $-326.62 Mil (As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Applied Genetic Technologies Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Applied Genetic Technologies's retained earnings for the quarter that ended in Sep. 2022 was $-326.62 Mil.

Applied Genetic Technologies's quarterly retained earnings declined from Mar. 2022 ($-289.83 Mil) to Jun. 2022 ($-308.21 Mil) and declined from Jun. 2022 ($-308.21 Mil) to Sep. 2022 ($-326.62 Mil).

Applied Genetic Technologies's annual retained earnings declined from Jun. 2020 ($-181.44 Mil) to Jun. 2021 ($-239.27 Mil) and declined from Jun. 2021 ($-239.27 Mil) to Jun. 2022 ($-308.21 Mil).


Applied Genetic Technologies Retained Earnings Historical Data

The historical data trend for Applied Genetic Technologies's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Genetic Technologies Retained Earnings Chart

Applied Genetic Technologies Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -110.93 -135.55 -181.44 -239.27 -308.21

Applied Genetic Technologies Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -256.39 -275.53 -289.83 -308.21 -326.62

Applied Genetic Technologies Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Applied Genetic Technologies  (NAS:AGTC) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Applied Genetic Technologies (Applied Genetic Technologies) Business Description

Traded in Other Exchanges
N/A
Address
14193 NW 119th Terrace, Suite 10, Alachua, FL, USA, 32615
Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 and ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.
Executives
Susan Schneider officer: Chief Medical Officer C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Jonathan I Lieber officer: Chief Financial Officer C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
Stephen W Potter officer: See Remarks 7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046
Gerald Anthony Reynolds officer: Chief Accounting Officer C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Susan B. Washer director, officer: President and CEO C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Hope Doyley-gay officer: General Counsel C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Abraham Scaria officer: Chief Scientific Officer C/O APPLIED GENETIC TECHNOLOGIES CORP, 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Yehia Hashad director C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
William Aliski director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Krol Patrick Johan Hendrik 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Privium Fund Management B.v. 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Aescap 2.0 Stichting 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Inspirational Visions B.v. 10 percent owner C/O PROQR THERAPEUTICS N.V., ZERNIKEDREEF 9, 2333 CK LEIDEN P7 2333
Brian Krex officer: General Counsel C/O AGTC, 14193 NW 119TH TERRACE, SUITE #10, ALACHUA FL 32615

Applied Genetic Technologies (Applied Genetic Technologies) Headlines